Cellectis SA (CLLS) has released an update.
Cellectis SA, a clinical-stage biopharmaceutical company, has published research showcasing its breakthrough SMART DUAL CAR T-cell therapy designed to combat challenging solid tumors. The innovative therapy utilizes TALEN gene-editing technology to create allogeneic CAR T-cells targeting cancer-associated fibroblasts and tumor-associated antigens, demonstrating promising results in mice models without the previously concerning off-tumor toxicity. This advancement could mark a significant step in effectively treating solid tumors with CAR T-cell therapies.
For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.
